Allogeneic hematopoietic stem cell transplantation (HSCT) is well-established as a potentially curative treatment for @entity1 who have chronic @entity2800 . The success of @entity2213 and other @entity669 kinase inhibitors (TKI) as initial therapy has changed the treatment paradigm for this disease. Allogeneic hematopoietic transplants are now reserved for @entity1 whose disease does not respond optimally to TKI treatment. @entity1 whose disease does not have an optimal response to @entity2213 may respond to a second-generation TKI, @entity8947 or @entity10542 , and many achieve major or complete molecular and cytogenetic responses. The indication for allogeneic HSCT versus continued second-line therapy is not well-defined and is the subject of ongoing study. There has been continued progress in reducing the @entity137 and risks of HSCT with development of reduced-intensity regimens; transplants can be routinely performed in @entity1 up to the age of 75 years who are in fair general medical condition. Transplantation results from unrelated donors have improved, with survival rates similar that achieved with matched siblings. Results with haploidentical and cord blood transplants have markedly improved, and should be considered for @entity1 lacking a matched donor. Allogeneic hematopoietic transplants have the best chance to be curative in @entity1 with chronic phase that is under hematologic control with 80% disease-free survival; @entity1 progressing to the accelerated phase or blast crisis have a much poorer prognosis. Thus, HSCT should be considered for @entity1 with @entity2213 failure. @entity1 receiving second-line TKI therapy must be closely monitored and referred for transplantation if a complete cytogenetic response and major molecular response is not achieved. HSCT should be performed if feasible in @entity1 without a continued response to TKI treatment.

Allogeneic stem cell transplantation for chronic XXXX resistant to @entity669 kinase inhibitors.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8947 :: ('MESH:C488369', 'Chemical') :: ['dasatinib'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['myeloid leukemia'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib'] @entity10542 :: ('MESH:C498826', 'Chemical') :: ['nilotinib']
@entity2800 :: (MESH:D007951,Disease) :: ['myeloid leukemia']
